Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
Feature|Videos|September 9, 2026
ClaimGuardRx Supports Patient Affordability From the Start
Author(s)Matt Turner, Paysign
Key Takeaways
- Understand how ClaimGuardRx protects manufacturers from maximizer and accumulator diversion tactics.
- Learn how ClaimGuardRx's proprietary LLM and voice interface differ from general-purpose analytics tools.
Matt Turner shares how ClaimGuardRx is redefining patient affordability by turning claims data into a proactive defense against maximizers and accumulators.
Advertisement
Sponsored by Paysign
Matt Turner, President of Patient Affordability at Paysign, introduces ClaimGuardRx, a proprietary large language model (LLM) built to protect the value of every dollar in a manufacturer's affordability program. The platform's voice interface gives account teams instant, conversational access to claims intelligence that once took manual review to uncover. In this video, Turner outlines the product's long-term vision: the tool not only defends programs but shapes how they're designed, priced, and optimized from the start. Turner also shares where Paysign sees the platform heading next, from specialty pharmacy dynamics to hub integration and patient journey optimization.
Advertisement
Related to this article
The interleukin-6 receptor inhibitor gains a second indication, though one of two phase 3 trials missed its primary endpoint.
European regulators are increasing pressure on clinical trial sponsors to report study results on time, rolling out new monitoring, reminders and guidance as patient advocates welcome the progress but question whether stronger oversight and enforcement will follow.
Why “we’re safe” is the most dangerous assumption in medical benefit commercialization.
Fox Rothschild's Mark Wagner on why drug shortages are so hard to fix — from the definition gap to API dependency to three-year site approvals.
Incubate’s John Stanford on why MFN hits mid-sized pharma harder — fewer products to absorb margin hits and less access to cheap capital.
AstraZeneca will pay insitro $40 million upfront to apply AI to target discovery in MASH and cardiomyopathies, with no candidates named yet.
AI does not end uncertainty in pharma strategy. Its value depends on how well leaders blend it with experience and evidence while keeping judgment human.
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Taps insitro AI for MASH in Deal Worth Up to $1.5 Billion
2
The Impact That the Renewed Focus on Domestic Manufacturing Might Have on the Supply Chain
3
FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease
4
EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe
5